文献速递糖尿病肥胖与代谢综合征

美国糖尿病预防计划随机临床试验中生活方式和二甲双胍干预对2型糖尿病发病率长达21年的长期效果及效应异质性

Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-04-28

美国糖尿病预防计划(DPP)将3234例糖尿病前期成人随机分配至强化生活方式干预(ILS)、二甲双胍或安慰剂,3年内2型糖尿病发病率分别降低58%和31%。长期随访约21年显示,与安慰剂相比,ILS组糖尿病发病风险比为0.76,二甲双胍组为0.83,效果持续存在但逐渐趋同,且效应存在异质性。

要点

  • 随访21年,与安慰剂相比,ILS组糖尿病发病HR为0.76,二甲双胍组为0.83。
  • ILS组中位无糖尿病生存期延长3.5年,二甲双胍组延长2.5年。
  • 基线空腹血糖、HbA1c和风险指数较高者接受ILS的绝对效应更大,年轻者接受二甲双胍的绝对效应更大。

核心结论

  • DPP试验中观察到的大幅初始干预效果之后,21年累计糖尿病发病率持续降低,且干预效果根据部分基线变量存在异质性。

研究设计与样本

  • 美国糖尿病预防计划(DPP)为3年随机临床试验,纳入3234例糖尿病前期成人,后续以DPP结局研究(DPPOS)继续随访,本分析纳入3195例参与者。
  • DPPOS中安慰剂组停止干预,二甲双胍组继续服用二甲双胍850 mg每日两次(如可耐受),ILS组每年接受两次小组强化课程,所有参与者每年接受四次小组生活方式干预。
  • 预设主要结局为按美国糖尿病协会标准定义的糖尿病发病率,分析采用意向性治疗,随访时间从1996年7月31日至2020年2月23日。

主要发现

  • 中位随访8.0年(IQR 3.0至18.0),个体随访时间0.2至23.2年,因行政删失21年后剩余风险人数急剧减少,随访视为代表21年期间。
  • 与安慰剂相比,原ILS组糖尿病发病HR为0.76(95%CI 0.68至0.85),率差为每100人年-1.59例(95%CI -2.25至-0.93);原二甲双胍组HR为0.83(95%CI 0.74至0.93),率差为每100人年-1.17例(95%CI -1.85至-0.49)。
  • ILS组和二甲双胍组中位无糖尿病生存期分别延长3.5年和2.5年,平均无糖尿病生存期分别延长2.0年(95%CI 1.2至2.8)和1.2年(95%CI 0.4至2.0)。
  • 糖尿病累计发病率曲线早期分离,尤其前3年二甲双胍组和ILS组发病率低于安慰剂组,随随访延长二甲双胍和ILS曲线逐渐趋同。
  • 绝对干预效应(率差)在基线空腹血糖、HbA1c及多变量临床和生理风险指数较高者中ILS更大,在较年轻参与者中二甲双胍更大。

局限性

  • 21年后因行政删失剩余风险人数急剧减少,随访被视为代表21年期间。
  • 干预效果根据部分基线变量存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the US Diabetes Prevention Program (DPP), a 3-year randomised clinical trial in 3234 adults with prediabetes, type 2 diabetes incidence was reduced by 58% with intensive lifestyle intervention (ILS) and by 31% with metformin, compared with placebo. We sought to assess the long-term effects and potential heterogeneity of treatment effects over approximately 21 years of follow-up. METHODS: The DPP trial was continued with protocol modifications as the DPP Outcomes Study (DPPOS). In the DPPOS, placebo was discontinued, metformin (850 mg twice a day as tolerated) was continued after unmasking, and group-based booster intervention classes were offered to the ILS group twice a year; additionally, all participants were offered group-based lifestyle intervention four times a year. The prespecified primary outcome during DPP and DPPOS was diabetes incidence defined by American Diabetes Association criteria. The DPPOS protocol specified continued diabetes incidence as an outcome; Feb 23, 2020, was chosen as the closing date for the present analysis, as a date prior to the COVID-19 pandemic, which caused major disruptions in clinic visits and complicated longitudinal data analyses. We assessed long-term persistence of intervention effects on diabetes incidence, and heterogeneity of effects in subgroups defined by baseline diabetes risk factors. Follow-up is reported for the combined study from July 31, 1996, to Feb 23, 2020, and analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, NCT00004992 (DPP) and NCT00038727 (DPPOS); follow-up is ongoing but the trial is closed to enrolment except for previous DPP participants. FINDINGS: 3195 participants originally enrolled in the DPP were included in the present analyses. This population comprised 2171 (67·9%) female participants and 1024 (32·1%) male participants, with a mean baseline age of 50·6 years (SD 10·7). Individual follow-up times ranged from 0·2 to 23·2 years (median 8·0 years [IQR 3·0 to 18·0]); remaining numbers at risk decreased sharply after 21 years because of administrative censoring and thus follow-up was considered to represent a 21-year period. During follow-up, compared with placebo, diabetes incidence rate was reduced in the original ILS group (hazard ratio [HR] 0·76 [95% CI 0·68 to 0·85], rate difference [RD] -1·59 cases [95% CI -2·25 to -0·93] per 100 person-years) and in the original metformin group (HR 0·83 [0·74 to 0·93], RD -1·17 [-1·85 to -0·49]), with corresponding increases in median diabetes-free survival of 3·5 years and 2·5 years, and mean diabetes-free survival of 2·0 years (95% CI 1·2 to 2·8) and 1·2 years (0·4 to 2·0), respectively. The diabetes cumulative incidence curves separated early, especially in the first 3 years, with lower incidence rates in the metformin and ILS groups than in the placebo group. The metformin and ILS curves progressively converged with longer follow-up. The overall treatment effects appeared to result from large early effects during the DPP. Absolute intervention effects, measured as RDs versus placebo, were greater with ILS in participants with higher values for baseline fasting glucose, HbA1c, and multivariable clinical and physiological risk indices, and with metformin in younger participants. INTERPRETATION: The large initial intervention effects seen in the DPP trial were followed by sustained reductions in cumulative diabetes incidence for 21 years. Intervention effects were heterogeneous according to some baseline variables. These findings could guide precision interventions to help address the current type 2 diabetes epidemic. FUNDING: US National Institute of Diabetes and Digestive and Kidney Diseases and other agencies. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Knowler WC, Doherty L, Edelstein SL, et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025. PMID: 40311647. doi:10.1016/S2213-8587(25)00022-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。